Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications

PLoS One. 2013;8(2):e55688. doi: 10.1371/journal.pone.0055688. Epub 2013 Feb 6.

Abstract

Background: Thrombin generation assay is a convenient and widely used method for analysis of the blood coagulation system status. Thrombin generation curve (TGC) is usually bell-shaped with a single peak, but there are exceptions. In particular, TGC in platelet-rich plasma (PRP) can sometimes have two peaks.

Objective: We sought to understand the mechanism underlying the occurrence of two peaks in the PRP thrombin generation curve.

Methods: Tissue factor-induced thrombin generation in PRP and platelet-poor plasma (PPP) was monitored using continuous measurement of the hydrolysis rate of the thrombin-specific fluorogenic substrate Z-Gly-Gly-Arg-AMC. Expression of phosphatidylserine (PS) and CD62P on the surface of activated platelets was measured by flow cytometry using corresponding fluorescently labeled markers.

Results: The addition of the P(2)Y(12) receptor antagonist MeS-AMP (160 µM), 83 nM prostaglandin E(1) (PGE(1)), or 1.6% DMSO to PRP caused the appearance of two peaks in the TGC. The PS exposure after thrombin activation on washed platelets in a suspension supplemented with DMSO, PGE(1) or MeS-AMP was delayed, which could indicate mechanism of the second peak formation. Supplementation of PRP with 1.6% DMSO plus 830 nM PGE(1) mediated the disappearance of the second peak and decreased the amplitude of the first peak. Increasing the platelet concentration in the PRP promoted the consolidation of the two peaks into one.

Conclusions: Procoagulant tenase and prothrombinase complexes in PRP assemble on phospholipid surfaces containing PS of two types--plasma lipoproteins and the surface of activated platelets. Thrombin generation in the PRP can be two-peaked. The second peak appears in the presence of platelet antagonists as a result of delayed PS expression on platelets, which leads to delayed assembly of the membrane-dependent procoagulant complexes and a second wave of thrombin generation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alprostadil / pharmacology
  • Coumarins / pharmacology
  • Factor V / drug effects*
  • Factor Xa / drug effects*
  • Flow Cytometry
  • Hemostatics / pharmacology
  • Humans
  • Oligopeptides / pharmacology
  • P-Selectin / metabolism
  • Phosphatidylserines / metabolism*
  • Platelet Activation / drug effects
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet-Rich Plasma / drug effects
  • Platelet-Rich Plasma / metabolism*
  • Thrombin / metabolism*
  • Thromboplastin / pharmacology

Substances

  • Coumarins
  • Hemostatics
  • Oligopeptides
  • P-Selectin
  • Phosphatidylserines
  • Platelet Aggregation Inhibitors
  • benzyloxycarbonyl-glycyl--glycyl-arginine-4-methylcoumaryl-7-amide
  • prothrombinase complex
  • Factor V
  • Thromboplastin
  • Thrombin
  • Factor Xa
  • Alprostadil

Grants and funding

This work was supported in part by the Russian Foundation for Basic Research (RFBR) grants 10-01-91055, 11-04-00303, and 11-04-12080, as well as by the Fundamental Research Programs of the Presidium of the Russian Academy of Sciences “Molecular and cellular biology” and “Fundamental sciences for medicine”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.